Market research
CDY.AU Cellmid Limited
AU AUD Personal Products
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 1.06
- Dividend yield
- 0.0%
- Beta
- -1.44
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Personal Products
- Industry
- Consumer Staples
- ISIN
- AU000000CDY3
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 1.06
- Dividend yield
- 0.0%
- Beta
- -1.44
About
About Cellmid Limited
Cellmid Limited, a consumer health company, develops, manufactures, and markets anti-aging products for hair, skin, and wellbeing in Australia, the United States, China, and Japan. It develops and sales FGF5 inhibitor hair health and hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company markets its products through retailers and wholesalers, as well as through a direct-to-consumer, e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.
Research context
Cellmid Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Personal Products
- Industry
- Consumer Staples
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CDY.AU discussion.
5 years, 6 months ago
Cellmid Limited is currently in a long term downtrend where the price is trading 33.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Cellmid Limited's total revenue sank by 23.7% to $3M since the same quarter in the previous year.
Its net income has dropped by 71.3% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 24.2% to $-994K since the same quarter in the previous year.
Based on the above factors, Cellmid Limited gets an overall score of 1/5.